Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936787 | 0.91 | SCN9A (0.45) | SCN9AKCNH2SCN5AAURKA | |
| SCHEMBL2281702 | 0.83 | IKBKB (0.46) | AURKAIKBKBMAPK8MAPK10AURKB | |
| SCHEMBL2288810 | 0.80 | IKBKB (0.47) | KCNH2AURKAIKBKBMAPK8MAPK10 | |
| SCHEMBL2287314 | 0.78 | IKBKB (0.46) | AURKAIKBKBMAPK8MAPK10AURKB | |
| SCHEMBL16390879 | 0.77 | IKBKB (0.55) | IKBKBMAPK8MAPK10JAK2JAK3 | |
| SCHEMBL3226666 | 0.77 | SCN9A (0.54) | SCN9AKCNH2SCN5AAURKAIKBKB | |
| SCHEMBL2285819 | 0.77 | CDK2 (0.50) | KCNH2AURKAIKBKBMAPK8MAPK10 | |
| SCHEMBL2285611 | 0.77 | CDK2 (0.47) | AURKAIKBKBMAPK8MAPK10EGFR | |
| SCHEMBL2354961 | 0.77 | JAK2 (0.48) | AURKAIKBKBAURKBJAK2JAK3 | |
| SCHEMBL12354945 | 0.75 | IGF1R (0.49) | SCN9AKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SCN9A 1091/4885KCNH2 156/4885SCN5A 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.